Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
May 2021
Historique:
revised: 20 02 2021
received: 14 12 2020
accepted: 22 02 2021
pubmed: 12 3 2021
medline: 12 10 2021
entrez: 11 3 2021
Statut: ppublish

Résumé

Limited real-world data exist on healthcare resource utilization (HCRU) and associated costs of patients with heart failure (HF) with reduced ejection fraction (HFrEF) and preserved EF (HFpEF), including urgent HF visits, which are assumed to be less burdensome than HF hospitalizations (hHFs) HYPOTHESIS: This study aimed to quantify the economic burden of HFrEF and HFpEF, via a retrospective, longitudinal cohort study, using IBM® linked claims/electronic health records (Commercial and Medicare Supplemental data only). Adult patients, indexed on HF diagnosis (ICD-10-CM: I50.x) from July 2012 through June 2018, with 6-month minimum baseline period and varying follow-up, were classified as HFrEF (I50.2x) or HFpEF (I50.3x) according to last-observed EF-specific diagnosis. HCRU/costs were assessed during follow-up. About 109 721 HF patients (22% HFrEF, 31% HFpEF, 47% unclassified EF; median 18 months' follow-up) were identified. There were 3.2 all-cause outpatient visits per patient-month (HFrEF, 3.3; HFpEF, 3.6); 69% of patients required inpatient stays (HFrEF, 80%; HFpEF, 78%). Overall, 11% of patients experienced hHFs (HFrEF, 23%; HFpEF, 16%), 9% experienced urgent HF visits (HFrEF, 15%; HFpEF, 12%); 26% were hospitalized less than 30 days after first urgent HF visit versus 11% after first hHF. Mean monthly total direct healthcare cost per patient was $9290 (HFrEF, $11 053; HFpEF, $7482). HF-related HCRU is substantial among contemporary real-world HF patients in US Commercial or Medicare supplemental health plans. Patients managed in urgent HF settings were over twice as likely to be hospitalized within 30 days versus those initially hospitalized, suggesting urgent HF visits are important clinical events and quality improvement targets.

Sections du résumé

BACKGROUND BACKGROUND
Limited real-world data exist on healthcare resource utilization (HCRU) and associated costs of patients with heart failure (HF) with reduced ejection fraction (HFrEF) and preserved EF (HFpEF), including urgent HF visits, which are assumed to be less burdensome than HF hospitalizations (hHFs) HYPOTHESIS: This study aimed to quantify the economic burden of HFrEF and HFpEF, via a retrospective, longitudinal cohort study, using IBM® linked claims/electronic health records (Commercial and Medicare Supplemental data only).
METHODS METHODS
Adult patients, indexed on HF diagnosis (ICD-10-CM: I50.x) from July 2012 through June 2018, with 6-month minimum baseline period and varying follow-up, were classified as HFrEF (I50.2x) or HFpEF (I50.3x) according to last-observed EF-specific diagnosis. HCRU/costs were assessed during follow-up.
RESULTS RESULTS
About 109 721 HF patients (22% HFrEF, 31% HFpEF, 47% unclassified EF; median 18 months' follow-up) were identified. There were 3.2 all-cause outpatient visits per patient-month (HFrEF, 3.3; HFpEF, 3.6); 69% of patients required inpatient stays (HFrEF, 80%; HFpEF, 78%). Overall, 11% of patients experienced hHFs (HFrEF, 23%; HFpEF, 16%), 9% experienced urgent HF visits (HFrEF, 15%; HFpEF, 12%); 26% were hospitalized less than 30 days after first urgent HF visit versus 11% after first hHF. Mean monthly total direct healthcare cost per patient was $9290 (HFrEF, $11 053; HFpEF, $7482).
CONCLUSIONS CONCLUSIONS
HF-related HCRU is substantial among contemporary real-world HF patients in US Commercial or Medicare supplemental health plans. Patients managed in urgent HF settings were over twice as likely to be hospitalized within 30 days versus those initially hospitalized, suggesting urgent HF visits are important clinical events and quality improvement targets.

Identifiants

pubmed: 33704817
doi: 10.1002/clc.23585
pmc: PMC8119853
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-655

Subventions

Organisme : AstraZeneca

Informations de copyright

© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Références

Adv Ther. 2020 Sep;37(9):4015-4032
pubmed: 32761552
Circ Res. 2019 May 24;124(11):1598-1617
pubmed: 31120821
J Am Coll Cardiol. 2019 Mar 12;73(9):1101-1103
pubmed: 30846106
Heart. 2016 Nov 15;102(22):1820-1825
pubmed: 27357124
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018
pubmed: 30103979
Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004700
pubmed: 30562067
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
J Am Coll Cardiol. 2019 Aug 6;74(5):601-612
pubmed: 31370950
JAMA. 2010 Jun 2;303(21):2141-7
pubmed: 20516414
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Circulation. 2018 Dec 11;138(24):2763-2773
pubmed: 30565987
Int J Cardiol. 2016 Jan 1;202:918-21
pubmed: 26479959
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Cardiovasc Endocrinol Metab. 2020 Feb 21;9(1):17-23
pubmed: 32104787
Clin Cardiol. 2021 May;44(5):646-655
pubmed: 33704817
J Cardiovasc Nurs. 2017 Jul/Aug;32(4):372-382
pubmed: 27617564
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Clin Cardiol. 2019 Dec;42(12):1155-1161
pubmed: 31524968
Lancet Glob Health. 2020 Mar;8(3):e411-e422
pubmed: 32087174
JACC Heart Fail. 2019 Jan;7(1):13-21
pubmed: 30606482
BMC Cardiovasc Disord. 2018 May 2;18(1):74
pubmed: 29716540
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
Circ Heart Fail. 2018 Dec;11(12):e004873
pubmed: 30562099
JAMA. 2013 Jan 23;309(4):355-63
pubmed: 23340637

Auteurs

Carolyn S P Lam (CSP)

National Heart Centre Singapore & Duke-National University of Singapore Medical School, Singapore.
University Medical Centre, Groningen, The Netherlands.

Robert Wood (R)

Adelphi Real World, Bollington, UK.

Muthiah Vaduganathan (M)

AstraZeneca, Gaithersburg (Consultant), Maryland, USA.
Division of Cardiovascular Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Massachusetts, USA.

Hector Bueno (H)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
CIBER de Enfermedades CardioVasculares (CIBERCV), Madrid, Spain.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Alex Chin (A)

AstraZeneca, Gaithersburg (Consultant), Maryland, USA.

Gabriela Luporini Saraiva (G)

AstraZeneca, Gaithersburg (Consultant), Maryland, USA.

Elisabeth Sörstadius (E)

AstraZeneca, Gothenburg, Sweden.

Theo Tritton (T)

Adelphi Real World, Bollington, UK.

Joseph Thomas (J)

Adelphi Real World, Bollington, UK.

Lei Qin (L)

AstraZeneca, Gaithersburg (Consultant), Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH